Your medical rep spends 40 minutes on the call entry. The doctor gave them 4. The category sold call-reporting and called it CRM. Ours reads the visit, the prescription pattern, the marketing engagement and the adverse-event signal, then tells the next rep walking in exactly what to do.
The Tier-1 KOL and the Tier-3 prescriber both got the same brand deck on the same Tuesday. The first opened slide three. The second filed it. The brand team called the campaign a success because both visits were “completed”.
Every Salesforce-built pharma CRM mistakes the form for the work. The rep types history, products discussed, samples left, follow-up plan, attendance. The form is satisfied. The HCP relationship is not. The brand team gets a beautiful activity dashboard at the end of the quarter. It does not show what the doctor thought of the conversation, what they wrote in their script three days later, or whether anyone is going to come back. The form is not the work. The decision the rep was supposed to make is what the work was. That decision is what UNFYD.PHARM gives back.
The therapy-area lead is on a competitor’s payroll. The publication count has not been updated in a year. The list refreshes when somebody complains, not when the science moves. KOL tiering is the most under-instrumented decision in pharma commercial.
Your CRM tracked every call. None of it told the rep what to say.
Innovator pharma, generics and specialty teams all run the same instrumentation, ask the same field-force questions and end every quarter on the same line of the brand P&L. The instrumentation was never the missing piece. UNFYD.PHARM is the field-decision layer that gets engineered around the existing stack, reading every signal pharma already generates and deciding the next action across the rep, the MSL, the brand team and the territory.
See The Medical & Care DepthPatient identifiers and prescriber data are masked at inbound, before a single token reaches the model. Our respectful AI reads the pattern. It does not read the patient. Your DPO, your DCGI auditor and your medical-affairs lead all get the same answer: nothing protected was exposed to make the field-action possible.
Before the rep walks into the visit, the brief is on their phone. What this HCP has prescribed. What this HCP has reacted to. Which content was opened, which was filed. Which competitor is at the door this week. The visit starts where it should, not where the last rep left it.
Publications, advisory-board attendance, peer-citation, prescribing strength and influence-on-cohort, refreshed every week. The Tier-1 list is a live ranking, not a static slide. PHARM does the reading the brand team does not have time for.
Adverse-event language in a rep note, an HCP email, a call transcript or a sample-feedback form is detected in real time and routed to medical safety. Not at month-end, not at the next pharmacovigilance review. In front of medical affairs, the day it surfaces.
Every detail aid, every approved e-mail, every speaker-program slide is tracked at the HCP level for opens, dwell, share, recall and follow-on prescription. The marketing budget stops funding the content nobody read, and re-prices what actually moved the script.
The medical rep, the MSL, the brand team and the territory manager share one HCP record. The MSL knows what the rep said. The brand team knows what the MSL escalated. The HCP stops getting the same brand story 4 times in 3 weeks.
COMPASS in the rep’s pocket. Pre-call brief, KOL profile, sample inventory, content library and adverse-event capture, in one tap. Designed for the visit, not retrofitted from a desktop CRM. Frees 12-15 productive hours per rep, per week. At scale, that is a coverage expansion of 1.4x without adding a single head.
The project management and operations platform for the cross-functional pods pharma leadership calls when it gets critical. Brand, medical, field, regulatory and HR share one operating record. Launch cycles compress by a quarter. Approval queues collapse from 7 inboxes into 1.
Every signal from the field, rep notes, prescription patterns, marketing engagement, KOL context, sample movement and adverse-event language, feeds one decisioning surface. The pre-call brief is on the rep’s phone before the visit. The post-call learning is on the brand team’s screen by the same evening. Patient and prescriber data are masked at entry, by default.
The category norm is a 4-6 quarter CRM-configuration cycle for every molecule launch. PHARM goes live on a measurable cohort in weeks. The brand team launches in the same year it plans.
PHARM does not replace your call-reporting system. It reads from it, decides on top of it and writes back to it. The reps keep the screen they know. The IT lead keeps the integration map they already approved. Time-to-value lands on a quarter, not a Veeva cycle.
English plus 11 Indian languages on the same model. The rep who writes call notes in Marathi or Tamil gets the same comprehension as the one who writes in English. No translation step. No regional re-training cycle.
The brand, medical, sales and market-access pods get their own view, their own approvals and their own outcomes on the same customer record. The pods that leadership drops into critical moments stop fighting CRM permissions and start sharing decisions.
PHI and prescriber data masked at the point of entry. DPDP, HIPAA and DCGI alignment as the default. Your medical-affairs lead and your DPO sign the same compliance report.
Multi-tenant or dedicated hosting, auto-scaling and a 99.9% SLA. The fast path when time-to-value matters most.
Full deployment inside your own data centre. Complete data sovereignty, no third-party cloud dependency. The deployment regulators sign off without a redline.
Processing and storage split across an on-premise core and cloud edge, for mixed compliance needs across business units.
Granular RBAC across users, teams, channels and campaign types, with full audit logging.
Architecture aligned to the frameworks regulated enterprises are measured against.
Data held within specified geographic boundaries for GDPR, PDPA and RBI requirements.
Enterprise identity across every UNFYD module via your existing directory.
AES-256 at rest, TLS 1.3 in transit, end-to-end encrypted campaign payloads.
Active-passive DR with automated failover and an RPO under 4 hours across all modes.